• Baricitinib EUA shakes up COVID-19 therapy: What ID physicians, intensivists need to know

    1 month ago - By Healio

    On the evening of Nov. 19, the FDA issued an emergency use authorization for the rheumatoid arthritis drug baricitinib in combination with remdesivir for patients hospitalized with suspected or confirmed COVID-19.
    Although this news was no doubt exciting for many who are eager for more available treatments against COVID-19, the decision came as a shock to some within the rheumatology field, who are still waiting for additional, and stronger, data on the safety and efficacy of janus kinase inhibitors in COVID-19.
    “Since the start of the pandemic, we as rheumatologists have been interested
    Read more ...